Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HUTCHMED (China) Limited (HK:0013)
HKEX:0013
HUTCHMED (China) Limited (0013) Stock Price & Analysis
1 Followers
0013 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$19.00 - HK$35.90
Previous CloseHK$29.05
Volume1.25M
Average Volume (3M)2.98M
Market Cap
HK$25.31B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)31.7
Beta1.66
Next Earnings
Jul 31, 2024EPS Estimate
-HK$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.92
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume2,982,319
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HUTCHMED (China) Limited News
PremiumCompany Announcements
HUTCHMED’s Drug Tazemetostat Nears China Market
PremiumCompany Announcements
HUTCHMED Files New SEC Registration Statement
PremiumCompany Announcements
HUTCHMED Announces Voting Rights and Global Focus
PremiumCompany Announcements
HUTCHMED Schedules 2024 Mid-Year Results Review
PremiumCompany Announcements
HUTCHMED Announces Upcoming R&D Event and Webinar
PremiumCompany Announcements
HUTCHMED’s Fruquintinib Wins EU Approval for Colorectal CancerOptions Prices
Currently, No data available
---
Ownership Overview
1.25% Insiders
1.99% Mutual Funds
2.22% Other Institutional Investors
94.53% Public Companies and
Individual Investors
0013 FAQ
What was HUTCHMED (China) Limited’s price range in the past 12 months?
HUTCHMED (China) Limited lowest stock price was HK$19.00 and its highest was HK$35.90 in the past 12 months.
What is HUTCHMED (China) Limited’s market cap?
Currently, no data Available
When is HUTCHMED (China) Limited’s upcoming earnings report date?
HUTCHMED (China) Limited’s upcoming earnings report date is Jul 31, 2024 which is in 4 days.
How were HUTCHMED (China) Limited’s earnings last quarter?
HUTCHMED (China) Limited released its earnings results on Feb 28, 2024. The company reported -HK$1.094 earnings per share for the quarter, beating the consensus estimate of -HK$1.687 by HK$0.594.
Is HUTCHMED (China) Limited overvalued?
According to Wall Street analysts HUTCHMED (China) Limited’s price is currently Overvalued.
Does HUTCHMED (China) Limited pay dividends?
HUTCHMED (China) Limited does not currently pay dividends.
What is HUTCHMED (China) Limited’s EPS estimate?
HUTCHMED (China) Limited’s EPS estimate is -HK$0.61.
How many shares outstanding does HUTCHMED (China) Limited have?
HUTCHMED (China) Limited has 871,359,740 shares outstanding.
What happened to HUTCHMED (China) Limited’s price movement after its last earnings report?
HUTCHMED (China) Limited reported an EPS of -HK$1.094 in its last earnings report, beating expectations of -HK$1.687. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of HUTCHMED (China) Limited?
Currently, no hedge funds are holding shares in HK:0013
---
HUTCHMED (China) Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.20%
12-Months-Change
Fundamentals
Return on Equity
15.29%
Trailing 12-Months
Asset Growth
17.31%
Trailing 12-Months
Company Description
HUTCHMED (China) Limited
Hutchison China Meditech is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
---
0013 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering 0013
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+14.93%
reiterated a buy rating 5 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +14.93% per trade.
---